Price
$176.05
Decreased by -1.1%
Dollar Volume (20D)
926.62 M
ADR%
1.86
Earnings Report Date (estimate)
Apr 25, 24
Shares Float
1.76 B
Shares Outstanding
1.77 B
Shares Short
14.75 M
Market Cap.
312.03 B
Beta
0.54
Price / Earnings
64.94
20D Range
162.67 179.89
50D Range
149.86 179.89
200D Range
127.03 179.89
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Feb 2, 24 2.79
Decreased by -22.5%
2.77
Increased by +0.72%
Oct 27, 23 2.95
Decreased by -19.4%
2.86
Increased by +3.15%
Jul 27, 23 2.91
Decreased by -13.65%
2.81
Increased by +3.56%
Apr 27, 23 2.46
Decreased by -24.07%
2.46
Feb 9, 23 3.6
Increased by +8.76%
3.56
Increased by +1.12%
Oct 28, 22 3.66
Increased by +9.91%
3.57
Increased by +2.52%
Jul 29, 22 3.37
Increased by +9.06%
3.31
Increased by +1.81%
Apr 29, 22 3.24
Increased by +9.83%
3.14
Increased by +3.18%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 23 14.3 B
Decreased by -5.42%
822 M
Decreased by -66.76%
Increased by +5.75%
Decreased by -64.86%
Sep 30, 23 13.93 B
Decreased by -5.97%
1.78 B
Decreased by -54.98%
Increased by +12.77%
Decreased by -52.11%
Jun 30, 23 13.87 B
Decreased by -4.92%
2.02 B
Increased by +119.05%
Increased by +14.6%
Increased by +130.39%
Mar 31, 23 12.22 B
Decreased by -9.7%
239 M
Decreased by -94.68%
Increased by +1.96%
Decreased by -94.11%
Dec 31, 22 15.12 B
Increased by +1.58%
2.47 B
Decreased by -38.85%
Increased by +16.35%
Decreased by -39.8%
Sep 30, 22 14.81 B
Increased by +3.28%
3.95 B
Increased by +24.22%
Increased by +26.66%
Increased by +20.28%
Jun 30, 22 14.58 B
Increased by +4.47%
924 M
Increased by +20.63%
Increased by +6.34%
Increased by +15.47%
Mar 31, 22 13.54 B
Increased by +4.06%
4.49 B
Increased by +26.3%
Increased by +33.17%
Increased by +21.38%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine with or without aura in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquarte